One molecule of glucose 6-phosphate inhibits brain hexokinase (HKI) with high affinity by binding to either one of two sites located in distinct halves of the enzyme. In addition to potent inhibition, glucose 6-phosphate releases HKI from the outer leaflet of mitochondria; however, the site of glucose 6-phosphate association responsible for the release of HKI is unclear. The incorporation of a C-terminal polyhistidine tag on HKI facilitates the rapid purification of recombinant enzyme from Escherichia coli. The tagged construct has N-formyl methionine as its first residue and has mitochondrial association properties comparable with native brain hexokinases. Release of wild-type and mutant hexokinases from mitochondria by glucose 6-phosphate follow equilibrium models, which explain the release phenomenon as the repartitioning of ligand-bound HKI between solution and the membrane. Mutations that block the binding of glucose 6-phosphate to the C-terminal half of HKI have little or no effect on the glucose 6-phosphate release. In contrast, mutations that block glucose 6-phosphate binding to the N-terminal half require ϳ7-fold higher concentrations of glucose 6-phosphate for the release of HKI. Results here implicate a primary role for the glucose 6-phosphate binding site at the N-terminal half of HKI in the release mechanism.
One molecule of glucose 6-phosphate inhibits brain hexokinase (HKI) with high affinity by binding to either one of two sites located in distinct halves of the enzyme. In addition to potent inhibition, glucose 6-phosphate releases HKI from the outer leaflet of mitochondria; however, the site of glucose 6-phosphate association responsible for the release of HKI is unclear. The incorporation of a C-terminal polyhistidine tag on HKI facilitates the rapid purification of recombinant enzyme from Escherichia coli. The tagged construct has N-formyl methionine as its first residue and has mitochondrial association properties comparable with native brain hexokinases. Release of wild-type and mutant hexokinases from mitochondria by glucose 6-phosphate follow equilibrium models, which explain the release phenomenon as the repartitioning of ligand-bound HKI between solution and the membrane. Mutations that block the binding of glucose 6-phosphate to the C-terminal half of HKI have little or no effect on the glucose 6-phosphate release. In contrast, mutations that block glucose 6-phosphate binding to the N-terminal half require ϳ7-fold higher concentrations of glucose 6-phosphate for the release of HKI. Results here implicate a primary role for the glucose 6-phosphate binding site at the N-terminal half of HKI in the release mechanism.
Brain tissue relies almost exclusively on glucose as its source of energy. Approximately 25% of circulating blood glucose and 20% of consumed oxygen is utilized by the brain, an organ that constitutes less than 2% of the human body mass (1) . Although four isozymes of hexokinase (ATP:D-hexose 6-phosphotransferase (2.7.1.1)) are present in mammals, brain tissue contains only a single isozyme, hexokinase I (HKI) 2 (2) (3) (4) . HKI is arguably the "pacemaker of glycolysis" in the brain and red blood cell (5) , and thus, its mechanism of action and its molecular regulation is of overriding significance. Glucose 6-phosphate (Glu-6-P) is not only a potent inhibitor of HKI at physiological concentrations, but it can release HKI from brain mitochondria (6) . The HKI-release function of Glu-6-P may be the first step in an enzyme degradation pathway (6) and/or a process linked to apoptosis (7) (8) (9) (10) .
X-ray crystallographic structures of HKI are available (11) (12) (13) (14) (15) . The wild-type enzymes are dimers of 100 kDa subunits (12) , but an engineered mutant HKI crystallizes as a monomer, adopting a conformation similar to that of the subunit of the dimer (14) . Hexokinase associated with the mitochondrial membrane may be a mixture of monomeric and tetrameric states (6, 16) , and possibly in one or both of these states, HKI could be associated with mitochondrial porin (16) . The enzyme is strongly inhibited by one of its reaction products, Glu-6-P, and this inhibition can be reversed by physiological concentrations of inorganic orthophosphate (6) . In fact, HKI may be inhibited 95-98% in vivo (5) . Mitochondrial association requires the first 15 amino acid residues at the N terminus of HKI. These residues are hydrophobic or without formal electrostatic charge, and could adopt a helical conformation (6, 17, 18) . Mitochondrial association gives HKI a competitive advantage relative to cytosolic transphosphorylases for mitochondrially synthesized ATP (13) . It is now known that HKI binds to the mitochondrion in proximity to porin and the translocator protein responsible for the ADP/ATP transport (6, 17, 18) .
The mechanism of Glu-6-P regulation of HKI has been a focal point of research from our laboratory since 1962 (20) . In 1951, Weil-Mahlerbe and Bone (21) reported Glu-6-P as a noncompetitive inhibitor of ATP (21) . On the basis of fundamental differences in the HKI recognition of glucose and Glu-6-P analogs, Crane and Sols (22) concluded Glu-6-P acted as an allosteric inhibitor. In 1962, Fromm and Zewe (20) demonstrated that Glu-6-P is, in fact, a competitive inhibitor of ATP and linear noncompetitive inhibitor of glucose, a finding subsequently confirmed by a number of investigators (3, (23) (24) (25) (26) (27) . Glu-6-P, acting as an allosteric inhibitor, is not in conflict with kinetics. Indeed, competitive inhibition merely demands mutual exclusivity in the binding of inhibitor and substrate to HKI (28) .
Problems in understanding the mechanism of Glu-6-P regulation of HKI have arisen over apparent contradictions regarding the number of Glu-6-P binding sites and their location. Equilibrium binding experiments from several groups show but one high affinity binding site for Glu-6-P on HKI, and yet all relevant crystal structures of HKI reveal bound molecules of Glu-6-P and glucose at the N-and C-terminal halves of the enzyme (12) (13) (14) (15) . Wilson (1, 29 -33) , a proponent of an inhibitory site for Glu-6-P at the N-terminal half, was among the first to show Glu-6-P inhibition of the truncated C-terminal half of HKI (34) . Data from several groups are in agreement: the kinetics of Glu-6-P inhibition of the truncated enzyme (C-terminal half) are virtually identical to those of full-length HKI. Several mutations in the Glu-6-P binding site in the N-terminal half of HKI eliminated P i relief of Glu-6-P inhibition, but had no effect on Glu-6-P inhibition (35) . Mutations of the Glu-6-P binding site in the C-half of HKI, however, also had no effect on Glu-6-P inhibition; only mutations at both Glu-6-P-binding sites resulted in the loss of inhibition (36) . To reconcile these observations, Liu et al. (36) suggested a coupling mechanism between the Nand C-terminal halves of HKI that mediate antagonistic interactions between the two Glu-6-P binding sites. Different functional contexts for HKI (as a monomer in solution, and quite possibly both a monomer and an oligomer on the mitochondrion) may favor different inhibitory mechanisms.
In addition to its role as a potent inhibitor of HKI, Glu-6-P is also capable of releasing mitochondrial-bound HKI (6). The molecular mechanism responsible for the release of HKI by Glu-6-P is unknown; however, it may be related to the conformational state of HKI observed with bound Glu-6-P (37). In particular, we were interested in the extent to which each Glu-6-P binding site participates in the release of HKI from the mitochondrion. To address this issue, we prepared mutants of HKI in which the two Glu-6-P binding loci were modified to preclude Glu-6-P binding. The results here show unequivocally that Glu-6-P binding to the N-terminal half is responsible for the release of recombinant human HKI from the mitochondrion.
EXPERIMENTAL PROCEDURES
Materials-ATP, NADP, Glu-6-P, glucose 1,6-bisphosphate, deoxyribonuclease (DNase I), leupeptin, and phenylmethylsulfonyl fluoride were from Sigma. Kanamycin sulfate was purchased from Invitrogen. DEAE HPLC resin was a product of Tosohaas. Nickel-nitrilotriacetic acid-agarose resin and Rosetta (DE3) competent cells were from Novagen. Glucose-6-phosphate dehydrogenase was obtained from Roche Molecular Biochemicals. Isopropyl 1-thio-␤-D-galactopyranoside was from Anatrace. The HKI inhibitor, 1,5-anhydroglucitol 6-phosphate (AnGlu-6-P), was available from a previous study (36) . Oligonucleotide synthesis and DNA sequencing were performed at the Iowa State University DNA Sequencing and Synthesis Facility.
Construction of Wild-type Hexokinase and Mutant Plasmids-Fulllength human brain hexokinase had been cloned into pET-11a in a previous study (38) . From this construct, the gene was cloned into pET24b, which contains a His 6 tail at the C terminus of the insertion site between the NdeI site and the EcoRI site, to produce pET-24b-HKI. The plasmid was then modified to add four additional histidine residues to increase the expressed affinity of the protein toward nickel-nitrilotriacetic acid-agarose. This modification was made through mutagenesis using PCR with the forward primer 5Ј-CAAGCTTGCGGCCGCACT-CGAGCACCACCACCACCACCACCACCACCACCACTGAGAT-CC-3Ј and its reverse compliment. The forward primers for the directed mutations Thr 232 3 Ala and Thr 536 3 Ala were 5Ј-GAAGTCGGCC-TGATCATCGGCGCTGGCACCAATGCTTGCTACAT-3Ј and 5Ј-GCCCTGGATCTTGGAGGAGCCAATTTCCGTGTGCTGCTGG-TGAAAATCC-3Ј, respectively (modified nucleotides underlined). A mutant, ␣ϩ2 HKI, with an extended connecting helix between the Nand C-halves of the enzyme, was made through two rounds of PCR mutagenesis, adding seven amino acids, or approximately two turns of ␣-helix, after position 466 of HKI. The first round added four amino acid residues, using the forward primer 5Ј-GCCTACCGCTTGGCCGAG-CAGCACATGAACCTGCACCGGCAGATAGAGGAGACCCTG-3Ј. The second primer inserted the remaining nine nucleotides with forward primer 5Ј-TGGCCGAGCAGCACATGAACCTGGCGGAA-CAGCACCGGCAGATAGAGGAGACCCTG-3Ј (the inserted codons are underlined). The Thr 232 3 Ala/␣ϩ2 combination mutant employed the above Thr 232 3 Ala primers on the ␣ϩ2 construct. The entire gene of each mutant as well as that of the wild-type enzyme was verified by sequencing.
Expression and Purification of Wild-type and Mutant Hexokinases-Wild-type or mutant pET-24b-HKI plasmids were transformed into Rosetta (DE3) cells, which were then grown in LB media at 37°C to an OD of 1.0. The temperature was then lowered to 16°C and isopropyl 1-thio-␤-D-galactopyranoside was added to a final concentration of 0.2 mM. Cells were harvested 16 -20 h after induction and resuspended in a lysis buffer of 25 mM NaH 2 PO 4 , pH 8.0, 300 mM NaCl, 2 mM glucose, 5 mM imidazole, and 1 mM dithiothreitol. In addition to the lysis buffer, 50 g/ml DNase I, 5 mM MgCl 2, 20 g/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride were added to the suspension. The cells were then lysed using a French press and centrifuged. The supernatant fluid was applied to a nickel-nitrilotriacetic acid-agarose column. The column was washed with 25 mM NaH 2 PO 4 , pH 8.0, 300 mM NaCl, 2 mM glucose, 40 mM imidazole, and 1 mM dithiothreitol, and then eluted with the same buffer containing 250 mM imidazole. The eluate was then dialyzed overnight in 25 mM KH 2 PO 4 /K 2 HPO 4 , pH 7.5, 2 mM glucose, and 2 mM ␤-mercaptoethanol. The protein was then applied to a preparative DEAE HPLC column as described previously (35) . The Iowa State University Protein Facility performed N-terminal sequencing on purified HKI. Prior to N-terminal sequencing, the protein was bound to a ProSorb sample preparation cartridge (PerkinElmer Life Sciences) containing a polyvinylidene difluoride membrane. The N terminus was deblocked by soaking the HKI-coated membrane in 0.6 M HCl overnight (39) .
Pig Liver Mitochondria Purification-Pig livers were obtained from the Iowa State University Meats Laboratory shortly after slaughter. Mitochondria were purified by the procedure of Graham (40) . Mitochondria were resuspended in the storage buffer with two modifications: no potassium phosphate was added, and the solution contained 5% Me 2 SO, which acts as a cryoprotectant (41) . The mitochondria were then flash frozen in dry ice-ethanol and stored at Ϫ80°C.
The HKI Activity Assay-Hexokinase activity was measured using the glucose-6-phosphate dehydrogenase-coupled spectrophotometric assay at pH 8.0 (20) . Hexokinase concentrations were determined by the Bradford method with bovine serum albumin as the standard (42) . Initial rate data were analyzed using the computer program GraFit (43) . For kinetic measurements of HKI on the mitochondrial membrane, whole mitochondria with bound hexokinase were added to the assay mixture and velocities were measured using the spectrophotometer. These data were fit by nonlinear least squares (using GraFit) to models described under "Results."
Circular Dichroism Spectra-Circular dichroism spectra were measured using a Jasco J710 circular dichroism spectrometer. The data were collected at room temperature between 200 and 260 nm. The concentration of HKI used in these measurements was 0.2 mg/ml in 2 mM HEPES, pH 7.8, with 0.2 mM glucose and 2 mM ␤-mercaptoethanol.
Mitochondrial Binding and Release-Prior to carrying out the binding experiments, HPLC-purified HKI was passed over a Sephadex G-50 column (Sigma) for desalting and to equilibrate the enzyme solution with the mitochondrial binding buffer, and then diluted to 2 mg/ml. The mitochondrial binding buffer contains 250 mM sucrose, 5 mM glucose, 5 mM MgCl 2 , and 5 mM HEPES, pH 7.4. Mitochondria were diluted into this buffer to a concentration of 3 mg/ml, wet weight. Purified HKI and mitochondria were mixed and allowed to stand for 90 min on ice, and then centrifuged at 10,000 ϫ g for 8 min. Unbound HKI in the supernatant fluid was decanted. Pelleted mitochondria were resuspended in mitochondrial binding buffer, less the MgCl 2 , and re-centrifuged. This wash step was repeated, after which pelleted mitochondria were resuspended in the mitochondrial binding buffer (MgCl 2 absent) and assayed for HKI activity (MgCl 2 included with ATP).
HKI release from the mitochondria was performed as follows. HKI was bound to mitochondria as above, and then resuspended in a release buffer containing 250 mM sucrose and 5 mM HEPES, pH 7.4. 100-l aliquots of this solution were distributed to plastic microcentrifuge tubes, to which Glu-6-P at various concentrations was added and allowed to sit for 30 min at room temperature. The mitochondria were pelleted by centrifugation. HKI solubilized by Glu-6-P was removed by decanting the supernatant liquid. The mitochondrial pellet was resuspended in 250 mM sucrose, 5 mM glucose, and 5 mM HEPES, pH 7.4, and centrifuged again. After discarding the supernatant fluid, pelleted mitochondria were resuspended, and then assayed for hexokinase activity.
For the mitochondrial release experiments, data for mutant HKI and wild-type HKI data were collected in parallel.
RESULTS
HKI Construction, Purification, and N-terminal Sequencing-Purified recombinant HKI used in crystallographic studies was a mixture of proteins beginning with either residue 10 or 12 of the translated DNA sequence (12) . As the initial 10 -12 residues are absolutely crucial for mitochondrial binding (44), the purified recombinant system used in crystallography can provide no information regarding mitochondrial association and release phenomena. With the intent of recovering fulllength HKI, a His-tagged HKI-pET-24b construct was prepared to facilitate rapid purification of recombinant enzyme. An initial construct with His 6 at the C terminus of HKI bound poorly to the nickel-nitrilotriacetic acid-agarose, but a 10-histidyl tag resulted in a construct with strong binding properties. After nickel-nitrilotriacetic acid-agarose and DEAE chromatography, protein purity was at least 95% as judged by SDS-polyacrylamide gel electrophoresis (data not shown). N-terminal sequencing of the purified protein returned no signal above background, indicating an N terminus chemically blocked from participation in the Edman degradation reaction. Deblocking of the N-formyl group in 0.6 M HCl was successful as evidenced by a clean amino acid sequence (MIAAQ) from five cycles of Edman degradation.
Rationale for the Selection of Mutants-As shown previously by Liu et al. (36) , the mutation Thr 536 3 Ala eliminates AnGlu-6-P inhibition of C-terminal half of HKI (TABLE ONE) . The mutation of Thr 232 3 Ala eliminates P i relief of AnGlu-6-P inhibition in the full-length HKI (35) . Either mutation alone has no effect on AnGlu-6-P inhibition of fulllength HKI, but when combined, the resulting mutant enzyme is not sensitive to AnGlu-6-P (36). Hence, AnGlu-6-P can bind to the N-terminal and/or C-terminal halves of HKI, in each case causing potent inhibition of catalysis by kinetic mechanisms that are competitive with ATP and noncompetitive with glucose (36) . Equilibrium binding studies in the presence and absence of glucose, however, indicate only one bound Glu-6-P molecule per HKI molecule (45) (46) (47) . Hence, the two Glu-6-P binding sites in the separate halves of HKI are coupled, allowing Glu-6-P to bind at only one of its two potential binding sites. The mutation at position 536 blocks Glu-6-P binding to the C-terminal half, whereas the mutation at position 232 blocks Glu-6-P binding to the N-terminal half.
The ␣ϩ2 mutation inserts a repeat of seven consecutive residues after position 466. The insertion is at the middle of the transition helix between the N-and C-terminal halves of HKI, and should add approximately two full turns to that ␣-helix. The insertion should separate the two halves of the ␣ϩ2 enzyme by an additional 11 Å while maintaining the relative orientation of the two halves observed in wild-type HKI. The mutation disrupts the coupling between Glu-6-P binding sites of the Nand C-terminal halves, i.e. inhibition of the ␣ϩ2 construct by AnGlu-6-P is competitive with ATP and noncompetitive with glucose, and as potent as AnGlu-6-P inhibition of the wild-type enzyme (TABLE ONE) . Unlike the wild-type enzyme, however, the mutation of Thr 536 to alanine in the ␣ϩ2 construct abolishes AnGlu-6-P inhibition. Hence, the coupling mechanism between the N-and C-terminal halves observed in wild-type HKI no longer operates in the ␣ϩ2 construct. Glu-6-P, by binding to the C-terminal half of HKI, could conceivably influence the conformation of the N-terminal half of the wild-type system by way of the N-half/C-half coupling mechanism, but that influence would be reduced severely or eliminated altogether in the ␣ϩ2 construct.
Kinetic Analysis of Wild-type and Mutant Enzymes-Kinetic parameters of the His-tagged construct are comparable with those reported for non-tagged HKI (TABLE ONE) . The small disparities between constructs in TABLE ONE are probably because of the His tag at the C terminus of HKI. AnGlu-6-P, which mimics the inhibition of Glu-6-P but is not a substrate for the coupled assay (48) , is a competitive inhibitor with respect to ATP and noncompetitive inhibitor with respect to glucose. The kinetic mechanisms of inhibition for the His-tagged construct are identical to those reported for the non-tagged enzyme. Mitochondrial Binding of HKI-Appropriately prepared liver mitochondria are devoid of native hexokinase activity (49) . His-tagged HKI, bound to mitochondria, increased hyperbolically with HKI concentration (Fig. 1) . The binding response curve of His-tagged HKI is comparable with that of the native enzyme (16) . At saturation, the specific activity of bound His-tagged HKI is 101 Ϯ 5 milliunits/mg of mitochondria, wet weight.
Glu-6-P-induced Release of Wild-type and Mutant HKI from
Mitochondria-Several models were considered to account for the observed release of wild-type and mutant HKI from mitochondria in response to increasing concentrations of Glu-6-P. The models fall into two general categories: (i) equilibrium models in which Glu-6-P, HKI (or a HKI mutant), and mitochondrial binding sites are in equilibrium or (ii) kinetic trap models in which a fraction of the bound HKI is nondissociating relative to the incubation time of the experiment (1 h). Incubation times of 20 and 40 min produced release curves identical to that of 30 min, indicating an equilibrium process as was found by Rose and Warms (6) . Ultimately, the simplest equilibrium model that can account for all observed phenomena associated with the Glu-6-P release of wild-type and mutant HKI from mitochondria is shown in Scheme I.
In Scheme 1, K1, K1 i , K i , and K ii are association constants, E represents wild-type or mutant HKI, and 1 M represents the concentration of a uniform class of mitochondrial binding sites for E. In Scheme 1 it is assumed that the formation of the quaternary complex E 1 MI 2 is precluded, i.e. binding of Glu-6-P to the HKI release site prevents binding of the enzyme to the mitochondrion.
The model can be generalized for n different types of mitochondrial binding sites, for instance, 1 M, 2 M, 3 M, . . . n M, by adding equilibrium relations in pairs comparable with the first two relationships above. The form of the mathematical equation used in data analysisis the same regardless of the number of distinct types of binding sites for E on the mitochondria. Using the equations above, the fraction of mitochondrial bound enzyme R as a function of [I] (concentration of Glu-6-P) is as follows.
The velocity of the enzyme reaction is assumed directly proportional to the fraction of bound enzyme. Hence, the observed velocity depends on the concentration of I as follows,
where a represents a proportionality constant with units of velocity. Equation 2 is of the general form, 
[I] for a model with n different types of mitochondrial binding sites for E. Equation 3 accounts for trends exhibited by the data. (i) In the absence of Glu-6-P, the concentration of free enzyme is small relative to the concentration of bound enzyme. Hence b must be large relative to unity, so that at
Hence, Equation 3 places a limit on the Glu-6-P release of bound enzyme. If K ii is not 0, then an infinite concentration of Glu-6-P would cause full release. As demonstrated below, the K ii term is significant, but small relative to c and K i for the wild-type enzyme. In contrast, K ii is indistinguishable from 0 for all mutant constructs considered here.
To compare the efficacy of Glu-6-P release for the various constructs of HKI, we define I 0.5 , the concentration of Glu-6-P necessary to release one-half of the bound fraction in the absence of an EI ϩ I ϭ EI 2 equilibrium. More precisely, we define V 0.5 as follows.
Using this definition of V 0.5 in Equation 3 (with K ii ϭ 0) we solve for I 0.5 , Hence, for all mutant enzymes, K ii was fixed to 0, with only a, b, and c as adjustable parameters. In contrast, the K ii value for the wild-type enzyme differed significantly from 0, necessitating fits with the full fourparameter model. Results of the analysis appear in TABLE TWO. Each release experiment for a mutant enzyme was done in parallel with an experiment for the wild-type enzyme. I 0.5 values for four separate preparations of recombinant wild-type enzyme, using the same preparation of mitochondria, ranged from 24 to 50 M. A plot of the wild-type data sets (Fig.  2 ) reveals similar curves displaced relative to each other. These curve displacements reflect systematic differences between preparations of wild-type enzyme, the origin of which is unclear. Curve displacements are not correlated with time as would be expected for an aging phenomenon associated with the mitochondria. Differences in I 0.5 and V 0.5 for the four wild-type data sets, however, are not significant relative to the standard deviations in their values. The average I 0.5 value over the four experiments for recombinant wild-type HKI is 35 M with a root mean square deviation of ϳ10 M. The mutation of Thr 232 to alanine increases I 0.5 by 7-fold over its corresponding wild-type value and 5-fold over the average I 0.5 value (TABLE TWO and Fig. 3 ). The Thr 232 3 Ala mutation in the ␣ϩ2 construct increases the I 0.5 value 13-fold relative to the average and corresponding wild-type values. In contrast, the I 0.5 value of Thr 536 3 Ala HKI does not differ significantly from that of the wild-type enzyme, and the difference in I 0.5 values of the wild-type and the ␣ϩ2 construct is of borderline significance. Limiting levels of release associated with the binding of a single molecule of Glu-6-P vary from 70 to 80% for the mutant constructs, and 50 -60% for the wild-type experiments. The highest concentrations of Glu-6-P (6 mM), however, ultimately cause levels of release for the wild-type enzyme comparable with those of the mutant constructs.
DISCUSSION
The present study is the first application of a recombinant HKI in the investigation of mitochondrial association and release phenomenon. The addition of the polyhistidyl tag to the C terminus of HKI facilitates rapid purification and minimizes the exposure of the enzyme to proteases from the Escherichia coli expression system. The protocol employed here results in recombinant enzymes with an N-formylated methionine taking the place of a presumed N-acetyl group at the N terminus of native human HKI. (Native rat enzyme likely has an N-acetyl group (44), and this is presumably a feature common to mammalian type I hexokinases.) The polyhistidyl-tagged wild-type enzyme binds to mitochondria in the presence of Mg 2ϩ , as reported for the native enzymes from several species (6, 50 -52) . The average I 0.5 value reported here (35 M) is comparable with that (ϳ50 M) estimated by FIGURE 2. Glu-6-P-induced release of wild-type HKI release from pig liver mitochondria. Mitochondria with HKI bound were suspended in 250 mM sucrose, 5 mM glucose, and 5 mM HEPES, pH 7.4, after exposure to varying concentrations of Glu-6-P. Plotted here are relative velocities from the mitochondrion bound HKI that remains after a 30-min incubation with Glu-6-P, the concentration of which is given as a base-10 logarithm. Each preparation of the recombinant wild-type enzyme was done in parallel with a specific mutant HKI as follows: the ␣ϩ2 construct (ࡗ), the Thr 232 3 Ala mutant enzyme (छ), the Thr 536 3 Ala mutant enzyme (f), and the ␣ϩ2/Thr 232 3 Ala mutant enzyme (Ⅺ). The solid lines represent fitted curves, using Equation 3 with parameters listed in TABLE TWO. G6P, Glu-6-P. FIGURE 3. Glu-6-P-induced release of wild-type and mutant HKIs from pig liver mitochondria. Mitochondria with HKI bound were suspended in 250 mM sucrose, 5 mM glucose, and 5 mM HEPES, pH 7.4, after exposure to varying concentrations of Glu-6-P. Plotted only are data from the concentration range 0 to 1 mM in Glu-6-P to focus on changes in relative velocity of greatest significance. In each panel, data for wild-type recombinant enzyme (f) is presented along with data from a mutant HKI done in parallel: panel A, Thr Rose and Warms (6) for the release of native hexokinase from S-37 ascites mitochondria. Moreover, the percentage of released enzyme from mitochondria, as a function of Glu-6-P concentration, is nearly identical for the recombinant human and ascites systems (6) . Glucose 1,6-bisphosphate, like Glu-6-P, is a powerful inhibitor of HKI (24, 26, 53) , and releases native hexokinase from the mitochondria of various rat tissues (54) . Glucose 1,6-bisphosphate also releases recombinant human HKI from porcine liver mitochondria, the release curve being qualitatively similar to that obtained with Glu-6-P (data not presented). Evidently, the C-terminal polyhistidyl tag and N-formyl methionine substitution does not alter mitochondrial binding properties, and have only a modest effect on kinetic parameters.
The mitochondrial binding properties of the mutant enzymes studied here allow a definitive conclusion: a mutation that impairs Glu-6-P association with the C-terminal half has no significant effect on the property of HKI release from the mitochondrial membrane, whereas a mutation that impairs Glu-6-P association with the N-terminal half increases the I 0.5 value by at least 5-fold. Evidently, the binding of Glu-6-P to the N-terminal half of HKI is primarily responsible for the release of HKI from the mitochondrial membrane. Conceivably, HKI may partition between a soluble state with Glu-6-P bound to the N-terminal half and a mitochondrial-associated state with Glu-6-P bound to the C-terminal half. If so, Glu-6-P inhibition of mitochondrial-bound HKI would occur at the active site, whereas inhibition of soluble HKI would occur at the allosteric site. Whether the role of the Glu-6-P binding site at the N-terminal half is exclusively for the release of enzyme from mitochondria, as hypothesized by Arora et al. (55) , or whether it also participates in the inhibition of catalysis both on and off the membrane is not settled by this or any other study.
The ␣ϩ2 construct decouples the N-and C-terminal halves of HKI. The mutation of Thr 536 to alanine abolishes Glu-6-P inhibition in the ␣ϩ2 construct, in contrast to the Thr 536 3 Ala mutation in the wildtype system, which retains potent Glu-6-P inhibition (TABLE ONE) . The I 0.5 value for the ␣ϩ2 construct is ϳ2-fold higher than that of the wild-type system (TABLE TWO) . Moreover, the I 0.5 value for the ␣ϩ2/ Thr 232 3 Ala construct is again ϳ2-fold greater than that of the Thr 232 3 Ala mutant enzyme. Although the differences (2-fold) are marginally significant, the trend is clear: the concentration of Glu-6-P necessary for the release of the ␣ϩ2 construct is higher than for the release of the wild-type enzyme. A number of factors can in principle be responsible for this phenomenon, but the one known difference between the wild-type and ␣ϩ2 constructs is the absence of a coupling mechanism between the N-and C-terminal halves for the latter system. Hence, the coupling mechanism could facilitate the release of wild-type HKI from mitochondria by Glu-6-P. Moreover, interactions between the N-terminal half and the mitochondrial membrane could be influenced by the conformational state of the C-terminal half.
The model used in the analysis of release data assumes an equilibrium between membrane-bound and soluble forms of the enzyme, as well as a single type of binding site on the mitochondria. Release of hexokinase is limited in this simple model by the equilibrium constant that reflects the balance in free energies of the HKI⅐Glu-6-P complexes in solution and on the membrane. HKI leaves the membrane because conformational changes wrought by the binding of Glu-6-P increase the free energy of the mitochondrial bound state relative to that of the solution state. A kinetic model, however, can also account for a limiting release of HKI: some fraction of the total bound HKI could be "stuck" on the membrane, because of an extremely slow step in a distinct release mechanism. The kinetic model is unlikely because ATP rapidly releases 90% of bound hexokinase from ascites mitochondria (6), and various salts also release nearly all bound HKI (6, 56, 57) . Hence, the limiting release of ϳ60% induced by Glu-6-P is most likely an equilibrium phenomenon.
The assumption of a single type of mitochondrial binding site is not justified by data from other investigations, but as pointed out under "Results," the fitting equation is not altered by the inclusion of multiple types of membrane-binding sites. If only a single type of site were to exist, then mitochondria with retained HKI would again exhibit a 60% release when exposed to Glu-6-P solutions with no soluble enzyme. No additional release, however, has been observed in such experiments (56) , and hence, any valid equilibrium model requires at least two kinds of binding sites on the mitochondria that recognize a single state of HKI or two different states of HKI that compete for a single type of mitochondrial binding site. Others (32) have recognized the necessity for at least two kinds of mitochondrial binding sites, but evidence also exists for multiple states of membrane-associated hexokinase. Indirect evidence from Rose and Warms (6) indicates releasable HKI is monomeric on the membrane and in solution, and results of cross-linking experiments (16) suggest the possibility of membrane-bound hexokinase tetramers.
Results here are consistent with a Glu-6-P-induced conformational change in the N-terminal half of HKI that releases the enzyme from the membrane. Conceivably, the membrane-bound N-terminal domain is in its open conformation. The binding of Glu-6-P drives a conformational change of the N-terminal half to its closed state with an apparent dissociation constant of 35 M. The conformational change in the N-terminal half disrupts critical interactions with the membrane mediated by Mg 2ϩ and/or the N-terminal segment of HKI. This scenario requires Glu-6-P to bind to HKI in solution with higher affinity than to the membrane-associated enzyme. The K d for the dissociation of Glu-6-P from HKI in solution (ϳ1 M, glucose present) is at least consistent with this requirement.
Nucleoside triphosphates and pyrophosphate probably work by mechanisms distinct from that of Glu-6-P-mediated release. Crystallographic investigations have identified an adenine-binding site near the N-terminal segment of HKI (14, 15) . ATP-mediated release of HKI, observed by Rose and Warms (6), may involve nucleotide interactions at this site. The single binding site for Mg 2ϩ , critical for the binding of HKI to the membrane, may be connected with this adenine binding site or may be located elsewhere on the HKI molecule. The effects of adenine nucleotides and Mg 2ϩ on HKI association/dissociation are potentially useful in mapping specific interactions between HKI and the mitochondrial membrane.
